117 related articles for article (PubMed ID: 37577531)
1. Mis-splicing Drives Loss of Function of p53
Lock IC; Leisenring NH; Floyd W; Xu ES; Luo L; Ma Y; Mansell EC; Cardona DM; Lee CL; Kirsch DG
bioRxiv; 2023 Aug; ():. PubMed ID: 37577531
[TBL] [Abstract][Full Text] [Related]
2. Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome.
Buzby JS; Williams SA; Schaffer L; Head SR; Nugent DJ
Cancer Genet; 2017 Feb; 211():9-17. PubMed ID: 28279309
[TBL] [Abstract][Full Text] [Related]
3. Unaffected Li-Fraumeni Syndrome Carrier Parent Demonstrates Allele-Specific mRNA Stabilization of Wild-Type
Buzby JS; Williams SA; Nugent DJ
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553570
[TBL] [Abstract][Full Text] [Related]
4. Aberrant p21WAF1-dependent growth arrest as the possible mechanism of abnormal resistance to ultraviolet light cytotoxicity in Li-Fraumeni syndrome fibroblast strains heterozygous for TP53 mutations.
Barley RD; Enns L; Paterson MC; Mirzayans R
Oncogene; 1998 Aug; 17(5):533-43. PubMed ID: 9704919
[TBL] [Abstract][Full Text] [Related]
5. Radiation-induced G1 arrest is not defective in fibroblasts from Li-Fraumeni families without TP53 mutations.
Boyle JM; Greaves MJ; Camplejohn RS; Birch JM; Roberts SA; Varley JM
Br J Cancer; 1999 Apr; 79(11-12):1657-64. PubMed ID: 10206274
[TBL] [Abstract][Full Text] [Related]
6. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
7. Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family.
Varley JM; Chapman P; McGown G; Thorncroft M; White GR; Greaves MJ; Scott D; Spreadborough A; Tricker KJ; Birch JM; Evans DG; Reddel R; Camplejohn RS; Burn J; Boyle JM
Oncogene; 1998 Jun; 16(25):3291-8. PubMed ID: 9681828
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of
Monti P; Menichini P; Speciale A; Cutrona G; Fais F; Taiana E; Neri A; Bomben R; Gentile M; Gattei V; Ferrarini M; Morabito F; Fronza G
Front Oncol; 2020; 10():593383. PubMed ID: 33194757
[TBL] [Abstract][Full Text] [Related]
9. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
10. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
11. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers.
Gudikote JP; Cascone T; Poteete A; Sitthideatphaiboon P; Wu Q; Morikawa N; Zhang F; Peng S; Tong P; Li L; Shen L; Nilsson M; Jones P; Sulman EP; Wang J; Bourdon JC; Johnson FM; Heymach JV
J Biol Chem; 2021 Nov; 297(5):101163. PubMed ID: 34481841
[TBL] [Abstract][Full Text] [Related]
13. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance.
Ford JM; Hanawalt PC
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8876-80. PubMed ID: 7568035
[TBL] [Abstract][Full Text] [Related]
14. MCG10, a novel p53 target gene that encodes a KH domain RNA-binding protein, is capable of inducing apoptosis and cell cycle arrest in G(2)-M.
Zhu J; Chen X
Mol Cell Biol; 2000 Aug; 20(15):5602-18. PubMed ID: 10891498
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53
Monti P; Ravera S; Speciale A; Velkova I; Foggetti G; Degan P; Fronza G; Menichini P
Front Genet; 2022; 13():974662. PubMed ID: 36226181
[TBL] [Abstract][Full Text] [Related]
16. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle arrest defect in Li-Fraumeni Syndrome: a mechanism of cancer predisposition?
Williams KJ; Boyle JM; Birch JM; Norton JD; Scott D
Oncogene; 1997 Jan; 14(3):277-82. PubMed ID: 9018113
[TBL] [Abstract][Full Text] [Related]
18. Potential therapeutic targets of
Tanaka T; Watanabe M; Yamashita K
Oncotarget; 2018 Mar; 9(22):16234-16247. PubMed ID: 29662640
[TBL] [Abstract][Full Text] [Related]
19. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
20. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
